vs
HERITAGE COMMERCE CORP（HTBK）与MESA LABORATORIES INC（MLAB）财务数据对比。点击上方公司名可切换其他公司
MESA LABORATORIES INC的季度营收约是HERITAGE COMMERCE CORP的1.2倍（$65.1M vs $53.6M），HERITAGE COMMERCE CORP净利率更高（28.2% vs 5.6%，领先22.6%），HERITAGE COMMERCE CORP同比增速更快（15.6% vs 3.6%），HERITAGE COMMERCE CORP自由现金流更多（$61.3M vs $18.0M），过去两年HERITAGE COMMERCE CORP的营收复合增速更高（12.8% vs 5.1%）
本文介绍的企业主体信息与内容描述不符，描述内容实际为美国商会，该商会成立于1912年4月23日，是美国规模最大的游说类商业协会 advocacy 团体，成立之初得益于时任总统威廉·霍华德·塔夫脱与劳工商务部长查尔斯·内格尔推动，旨在代表工商界发声。
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
HTBK vs MLAB — 直观对比
营收规模更大
MLAB
是对方的1.2倍
$53.6M
营收增速更快
HTBK
高出12.0%
3.6%
净利率更高
HTBK
高出22.6%
5.6%
自由现金流更多
HTBK
多$43.3M
$18.0M
两年增速更快
HTBK
近两年复合增速
5.1%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $53.6M | $65.1M |
| 净利润 | $15.1M | $3.6M |
| 毛利率 | — | 64.2% |
| 营业利润率 | 41.0% | 12.2% |
| 净利率 | 28.2% | 5.6% |
| 营收同比 | 15.6% | 3.6% |
| 净利润同比 | 42.3% | 316.6% |
| 每股收益（稀释后） | $0.25 | $0.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HTBKMLAB
| Q4 25 | $53.6M | $65.1M | ||
| Q3 25 | $50.0M | $60.7M | ||
| Q2 25 | $47.8M | $59.5M | ||
| Q1 25 | $46.1M | $62.1M | ||
| Q4 24 | $46.4M | $62.8M | ||
| Q3 24 | $42.2M | $57.8M | ||
| Q2 24 | $41.7M | $58.2M | ||
| Q1 24 | $42.1M | $58.9M |
净利润HTBKMLAB
| Q4 25 | $15.1M | $3.6M | ||
| Q3 25 | $14.7M | $2.5M | ||
| Q2 25 | $6.4M | $4.7M | ||
| Q1 25 | $11.6M | $-7.1M | ||
| Q4 24 | $10.6M | $-1.7M | ||
| Q3 24 | $10.5M | $3.4M | ||
| Q2 24 | $9.2M | $3.4M | ||
| Q1 24 | $10.2M | $-254.6M |
毛利率HTBKMLAB
| Q4 25 | — | 64.2% | ||
| Q3 25 | — | 61.5% | ||
| Q2 25 | — | 62.0% | ||
| Q1 25 | — | 61.8% | ||
| Q4 24 | — | 63.3% | ||
| Q3 24 | — | 61.3% | ||
| Q2 24 | — | 64.0% | ||
| Q1 24 | — | 62.1% |
营业利润率HTBKMLAB
| Q4 25 | 41.0% | 12.2% | ||
| Q3 25 | 41.1% | 7.8% | ||
| Q2 25 | 18.7% | 5.1% | ||
| Q1 25 | 35.4% | 2.4% | ||
| Q4 24 | 31.8% | 9.2% | ||
| Q3 24 | 34.3% | 6.1% | ||
| Q2 24 | 31.3% | 9.6% | ||
| Q1 24 | 34.2% | -460.6% |
净利率HTBKMLAB
| Q4 25 | 28.2% | 5.6% | ||
| Q3 25 | 29.4% | 4.1% | ||
| Q2 25 | 13.4% | 8.0% | ||
| Q1 25 | 25.2% | -11.4% | ||
| Q4 24 | 22.9% | -2.7% | ||
| Q3 24 | 24.9% | 5.9% | ||
| Q2 24 | 22.1% | 5.8% | ||
| Q1 24 | 24.1% | -432.2% |
每股收益（稀释后）HTBKMLAB
| Q4 25 | $0.25 | $0.65 | ||
| Q3 25 | $0.24 | $0.45 | ||
| Q2 25 | $0.10 | $0.85 | ||
| Q1 25 | $0.19 | $-1.30 | ||
| Q4 24 | $0.17 | $-0.31 | ||
| Q3 24 | $0.17 | $0.63 | ||
| Q2 24 | $0.15 | $0.62 | ||
| Q1 24 | $0.17 | $-47.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $29.0M |
| 总债务越低越好 | — | $68.4M |
| 股东权益账面价值 | $708.6M | $186.7M |
| 总资产 | $5.8B | $434.8M |
| 负债/权益比越低杠杆越低 | — | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资HTBKMLAB
| Q4 25 | — | $29.0M | ||
| Q3 25 | — | $20.4M | ||
| Q2 25 | — | $21.3M | ||
| Q1 25 | — | $27.3M | ||
| Q4 24 | — | $27.3M | ||
| Q3 24 | — | $24.3M | ||
| Q2 24 | — | $28.5M | ||
| Q1 24 | — | $28.2M |
总债务HTBKMLAB
| Q4 25 | — | $68.4M | ||
| Q3 25 | — | $69.4M | ||
| Q2 25 | — | $70.3M | ||
| Q1 25 | — | $71.3M | ||
| Q4 24 | — | $72.2M | ||
| Q3 24 | — | $73.1M | ||
| Q2 24 | — | $74.1M | ||
| Q1 24 | — | — |
股东权益HTBKMLAB
| Q4 25 | $708.6M | $186.7M | ||
| Q3 25 | $700.0M | $178.5M | ||
| Q2 25 | $694.7M | $172.5M | ||
| Q1 25 | $696.2M | $159.8M | ||
| Q4 24 | $689.7M | $155.2M | ||
| Q3 24 | $685.4M | $161.5M | ||
| Q2 24 | $679.2M | $150.7M | ||
| Q1 24 | $676.3M | $145.4M |
总资产HTBKMLAB
| Q4 25 | $5.8B | $434.8M | ||
| Q3 25 | $5.6B | $430.4M | ||
| Q2 25 | $5.5B | $435.7M | ||
| Q1 25 | $5.5B | $433.3M | ||
| Q4 24 | $5.6B | $433.3M | ||
| Q3 24 | $5.6B | $454.1M | ||
| Q2 24 | $5.3B | $440.4M | ||
| Q1 24 | $5.3B | $446.8M |
负债/权益比HTBKMLAB
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.49× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $61.7M | $18.8M |
| 自由现金流经营现金流 - 资本支出 | $61.3M | $18.0M |
| 自由现金流率自由现金流/营收 | 114.3% | 27.7% |
| 资本支出强度资本支出/营收 | 0.7% | 1.1% |
| 现金转化率经营现金流/净利润 | 4.08× | 5.17× |
| 过去12个月自由现金流最近4个季度 | — | $37.9M |
8季度趋势，按日历期对齐
经营现金流HTBKMLAB
| Q4 25 | $61.7M | $18.8M | ||
| Q3 25 | $18.9M | $8.2M | ||
| Q2 25 | $8.0M | $1.9M | ||
| Q1 25 | $14.8M | $12.7M | ||
| Q4 24 | $39.0M | $18.1M | ||
| Q3 24 | $5.3M | $5.3M | ||
| Q2 24 | $10.5M | $10.7M | ||
| Q1 24 | $7.3M | $12.9M |
自由现金流HTBKMLAB
| Q4 25 | $61.3M | $18.0M | ||
| Q3 25 | $18.8M | $7.1M | ||
| Q2 25 | — | $884.0K | ||
| Q1 25 | — | $11.9M | ||
| Q4 24 | $37.3M | $17.3M | ||
| Q3 24 | $4.9M | $3.5M | ||
| Q2 24 | $9.9M | $9.9M | ||
| Q1 24 | $6.9M | $12.3M |
自由现金流率HTBKMLAB
| Q4 25 | 114.3% | 27.7% | ||
| Q3 25 | 37.7% | 11.7% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 19.2% | ||
| Q4 24 | 80.5% | 27.6% | ||
| Q3 24 | 11.6% | 6.0% | ||
| Q2 24 | 23.6% | 16.9% | ||
| Q1 24 | 16.4% | 21.0% |
资本支出强度HTBKMLAB
| Q4 25 | 0.7% | 1.1% | ||
| Q3 25 | 0.1% | 1.8% | ||
| Q2 25 | — | 1.7% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | 3.5% | 1.3% | ||
| Q3 24 | 1.0% | 3.1% | ||
| Q2 24 | 1.6% | 1.5% | ||
| Q1 24 | 1.0% | 0.9% |
现金转化率HTBKMLAB
| Q4 25 | 4.08× | 5.17× | ||
| Q3 25 | 1.28× | 3.32× | ||
| Q2 25 | 1.25× | 0.40× | ||
| Q1 25 | 1.28× | — | ||
| Q4 24 | 3.67× | — | ||
| Q3 24 | 0.50× | 1.54× | ||
| Q2 24 | 1.14× | 3.17× | ||
| Q1 24 | 0.72× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HTBK
暂无分部数据
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
